-
Special dermatitis (AD) innovative therapy! Concorde Kirin pioneered THEX40 targeted single anti-KHK4083 Phase II clinical success!
Time of Update: 2021-02-23
February 19, 2021 // -- Kyowa Kirin, a Japanese pharmaceutical company, recently announced that phase 2 studies evaluating the antibody drug KHK4083 to treat adult patients with moderate to severe endexual dermatitis (AD) have reached the main endpoint.
-
New anti-inflammatory drugs! The FDA grants oral JAK/SYK dual-acting inhibitor ASN002 to treat the rapid pass of adiotic dermatitis:
Time of Update: 2021-02-17
Asana CEO and Founder Sandeep Gupta said, "We are pleased that the FDA has granted ASN002 fast track qualification, which reflects the importance of accelerating the development of new drugs to treat challenging skin/inflammatory diseases that have a significant impact on patient life." We look forward to interacting well with the FDA throughout the development of ASN002 and accelerating the clinical development of ASN002.
-
Sanofi/Regenerative new anti-inflammatory drug Dupixent treats adolescent endemic dermatitis (AD) Phase III clinically obtained:
Time of Update: 2021-02-15
Based on the Phase III study data, Sanofi and Regeneratives have filed regulatory filings for the use of Dupixent for moderate to severe AD treatment in adolescents (12-17 years of age).
-
A new drug for specific dermatitis (AD) itching! New anti-inflammatory drug: IL-31 receptor
Time of Update: 2020-07-17
!--webeditor:page title"--Twitterderitis (Photo: salinetherapy.com) July 12, 2020 // Maruho is a Japanese pharmaceutical company focused on the development of new drugs for dermatology , the company a
-
A new drug for adhesion dermatitis (AD) ! Leo Pharmaceuticals Anti-IL-13 Monotarokinumab: The first challenger of Nofi Dupixent biopharmaceuticals!
Time of Update: 2020-07-17
11, 2020 // Leo Pharma, a Danish pharmaceutical company, recently announced that the U.S Food and Drug Administration (FDA) has accepted a biological product licensing application (BLA) for tralokinum
-
Sanofi's IL-4/IL-13 mono-anti-Dupixent shows significant benefits in children with asexual dermatitis
Time of Update: 2020-05-29
Sanofi has released Phase III experimental data for its IL-4/IL-13 mono-anti-Dupixent (dupilumab) treatment for children with severe asexual dermatitis beyond control The results of the Phase III
-
New anti-inflammatory drugs! Sanofi/Regenerative Dupixent approved in the U.S.: The first
Time of Update: 2020-05-28
May 27, 2020 / Biogro BIOON/ -- Sanofi and Regeneron recently jointly announced that the U.S Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of patients aged
-
New anti-inflammatory drugs! Sanofi / regenerant dupixent is under priority review in the United
Time of Update: 2020-01-29
January 29, 2020 / BIOON/ --Sanofi and Zaihuan announced recently that the US Food and Drug Administration (FDA) has accepted and will give priority to examining a supplementary biological product lic
-
New anti-inflammatory drugs! The phase III clinical study on the treatment of atopic dermatitis (AD) with Lilly oral JAK inhibitor olumiant was successful!
Time of Update: 2020-01-28
January 28, 2020 / bioun / -- Eli Lilly, an American pharmaceutical giant, and Incyte, a partner, recently announced that breeze-ad4, a phase III clinical study to evaluate the treatment of moderate t
